GSK expands AI partnership with Tempus, fronting $70M for access to 'multimodal data'
GSK has been aggressively looking at AI, and in its newest venture, the Big Pharma has expanded a deal with an old partner in a bid to add to its capabilities.
The UK pharma put out word in the wee hours of Tuesday morning that it is broadening its partnership with AI outfit Tempus, which has specialized in de-identified patient data. Having worked together since 2020, GSK has paid Tempus $70 million upfront for three more years of partnership, with more investment possible and an option to extend the deal for yet another two years. This new deal, according to GSK, will focus on improving clinical trial design, speeding up enrollment and identifying drug targets.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
